Orallyactivenon-steroidalandrogenreceptorantagonist(IC50=190nM).DisplaysperipheralselectivityanddoesnoteffectserumlevelsofLHandtestosterone.Exhibitspotentanticanceractivityinvivo.
SoldforresearchpurposesonlyunderagreementfromAstraZeneca
BicalutamideisalsoofferedaspartoftheTocriscreenPlusandTocriscreenLibraryofFDA-ApprovedCompounds.FindoutmoreaboutcompoundlibrariesavailablefromTocris.
M.Wt | 430.37 |
Formula | C18H14F4N2O4S |
Storage | StoreatRT |
Purity | ≥99%(HPLC) |
CASNumber | 90357-06-5 |
PubChemID | 2375 |
InChIKey | LKJPYSCBVHEWIU-UHFFFAOYSA-N |
Smiles | O=C(C(O)(C)CS(C2=CC=C(F)C=C2)(=O)=O)NC1=CC(C(F)(F)F)=C(C#N)C=C1 |
Thetechnicaldataprovidedaboveisforguidanceonly.ForbatchspecificdatarefertotheCertificateofAnalysis.
AllTocrisproductsareintendedforlaboratoryresearchuseonly.
Solvent | MaxConc.mg/mL | MaxConc.mM | |
---|---|---|---|
Solubility | |||
DMSO | 43.04 | 100 | |
ethanol | 4.3 | 10 |
Thefollowingdataisbasedontheproductmolecularweight430.37.Batchspecificmolecularweightsmayvaryfrombatchtobatchduetosolventofhydration,whichwillaffectthesolventvolumesrequiredtopreparestocksolutions.
Concentration/SolventVolume/Mass | 1mg | 5mg | 10mg |
---|---|---|---|
1mM | 2.32mL | 11.62mL | 23.24mL |
5mM | 0.46mL | 2.32mL | 4.65mL |
10mM | 0.23mL | 1.16mL | 2.32mL |
50mM | 0.05mL | 0.23mL | 0.46mL |